Ana Rodriguez is an Infectious Disease physician. ClinicalTrials.gov lists 20 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1119 Broad St
Newark, NJ 071142501
Telephone
201-926-6899Registry record last updated 16 Jan 2017.
Clinical trials
- Impact of a Novel Functional Snack on Perimenopausal Symptoms and Well-being
Sponsor: King's College London
- Effects of Betalains on Cardiovascular Health and Quality of Life
Sponsor: King's College London
- Exercise Program for Maintaining Physical Function and Frailty on Dwelling Older Adults
Sponsor: University of the Basque Country (UPV/EHU)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20241 payment
- Cranial Technologies, IncProgram year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
34.2%Statin10.2%Atorvastatin Calcium93%Simvastatin7%Part D<11 patientsCalcium channel blocker5.5%Amlodipine Besylate100%Part D≥19 patients+ 10 more classes in this area
Nervous system
17.3%SSRI2.3%Escitalopram Oxalate42%Trazodone Hcl31%Citalopram Hbr27%Part D<11 patientsOther antidepressants2.1%Mirtazapine100%Part D<11 patients+ 12 more classes in this area
Metabolism & gastrointestinal
15.9%Insulin Analog3.8%Basaglar Kwikpen U-10032%Lantus Solostar26%Lantus22%Insulin Lispro21%Part D<11 patientsDPP-4 inhibitor3.7%Januvia81%Tradjenta19%Part D<11 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”